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Abstract
Background: Anaplastic lymphoma kinase (ALK) genomic alterations have emerged as a potent predictor of benefit from
treatment with ALK inhibitors in several cancers. Currently, there is no information about ALK gene alterations in urothelial
carcinoma (UC) and its correlation with clinical or pathologic features and outcome.
Methods: Samples from patients with advanced UC and correlative clinical data were collected. Genomic imbalances were
investigated by array comparative genomic hybridization (aCGH). ALK gene status was evaluated by fluorescence in situ
hybridization (FISH). ALK expression was assessed by immunohistochemistry (IHC) and high-throughput mutation analysis
with Oncomap 3 platform. Next generation sequencing was performed using Illumina Genome Analyzer IIx, and Illumina
HiSeq 2000 in the FISH positive case.
Results: 70 of 96 patients had tissue available for all the tests performed. Arm level copy number gains at chromosome 2
were identified in 17 (24%) patients. Minor copy number alterations (CNAs) in the proximity of ALK locus were found in 3
patients by aCGH. By FISH analysis, one of these samples had a deletion of the 59ALK. Whole genome next generation
sequencing was inconclusive to confirm the deletion at the level of the ALK gene at the coverage level used. We did not
observe an association between ALK CNA and overall survival, ECOG PS, or development of visceral disease.
Conclusions: ALK genomic alterations are rare and probably without prognostic implications in UC. The potential for testing
ALK inhibitors in UC merits further investigation but might be restricted to the identification of an enriched population.
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Introduction
Urothelial carcinoma (UC) accounts for 15,210 cancer deaths
per year in the United States [1]. Five-year survival for patients
with muscle invasive (T2) disease or greater is only 50%.
Advanced UC of the bladder is often associated with mutations
and multiple somatic copy number alterations [2]. Comparative
genomic hybridization studies of bladder carcinomas and cell lines
have revealed a number of recurrent genetic aberrations including
amplifications or gains on 8q22-24, 11q13, 17q21, and losses on
chromosomes 9, 8p22-23, and 17p6-9 [3,4]. In several clinical
cohorts, some of these genomic alterations have also been
associated with pathological stage and outcome [5].
In the recent years, potential new targets for treatment
intervention have been described in urothelial tumors. The
identification of driving genomic alterations as mutations even if
occurring in only a small subset of bladder cancer patients, may
lead to the development of patient-specific therapies as has been
the case of the recently described mutations in TSC1 predicting
response to mTOR inhibitors like everolimus [6–8]. Another
example is the PIK3CA gene, mutated in up to 26% of cases in the
PLOS ONE | www.plosone.org 1 August 2014 | Volume 9 | Issue 8 | e103325series by Ross and colleagues that may predict sensitivity to
PIK3CA/mTOR inhibitors [9].
The ALK (anaplastic lymphoma Kinase) inhibitor crizotinib,
has recently shown high efficacy in the treatment of patients with
non-small cell lung cancer (NSCLC) with ALK translocation
which is present in about 4–7% of the tumors [10–12]. In a phase
I study of NSCLC patients with an ALK translocation, the
response rate was 57% independent of performance status or
number of previous treatments with a 70% probability of
progression free survival at 6 months [13]. In several other tumor
types besides lung cancer, ALK genomic alterations have been
identified as potential oncogenic drivers, meaning that cancers in
different organs can be targeted for treatment with ALK inhibitors
regardless of their cell of origin.
In UC, ALK copy number gain, amplification, translocations,
mutations, or expression have not been characterized. We
therefore investigated ALK protein expression and underlying
genetic aberrations in a cohort of patients who received
chemotherapy in the setting of metastatic disease, focusing on
clinical and prognostic implications.
In the present study we show that ALK genomic alterations,
such as copy number alterations (CNA) and deletions, occur in
UC. Additionally, we attempted to identify the impact of these
alterations with clinical and outcome features.
Material and Methods
Patients
This project was approved by the local ethics committee (CEIC-
IMAS) at Hospital del Mar, and by the Dana-Farber/Harvard
Cancer Center (DF/HCC) institutional review board (IRB).
Because the majority of patients were died at the time of collecting
samples, a waiver of consent was requested and given from IRB of
DF/HCC for all participants (requiring complete deidentification
of the samples prior the analysis).
A cohort of 96 patients, with metastatic UC treated with
platinum-based combination was identified. All patients under-
went several treatment regimens, all containing gemcitabine and a
platinum compound, with some patients receiving additional
paclitaxel as well. Patient clinical data was collected. The final
cohort included 70 patients (52 males, 18 females) with available
clinical data and sufficient tissue samples to conduct all the
genomic studies.
Tumor Samples
The analysis was performed in formalin-fixed paraffin embed-
ded (FFPE) tissue from UC of the urinary tract. Other molecular
studies have been performed and reported in these samples in
order to characterize the biology of UC [14]. The specimens were
retrospectively retrieved from the pathology archive at Hospital
del Mar and Mar Biobank in Barcelona, Spain. Slides were
reviewed separately by two genitourinary specialist pathologists
(MS, DB). All patients had high grade transitional cell carcinoma
and no other histological variant was included in this study.
Tumor areas were evaluated by a single pathologist (DB) and
tumor bearing 0.6 mm cores were punched for DNA extraction
and/or tissue microarray (TMA) construction.
ALK analysis
ALK genomic alterations were evaluated by array comparative
genomic hibridization (aCGH), fluorescence in situ hybridization
(FISH), immunohistochemistry (IHC), mass spectrometry muta-
tion analysis and next-generation sequencing. Description of
methods can be found in the appendix (Methods S1).
Statistical analysis
Statistical analysis of clinical data and molecular features was
carried out with SAS version 9.2 (SAS Institute Inc, Cary, NC).
Patient and clinical characteristics were summarized as number
and percentages for categorical variables and median and inter-
quartile ranges for continuous variables. Overall survival (OS) was
defined from the date patients received first line chemotherapy for
advanced disease until date of death or censored on the last known
alive date. ALK copy number alteration was defined as having
more than a 4 fold change [15]. Fisher exact test was used to assess
the associations of ALK copy number alteration with ECOG PS
and whether patients developed visceral disease. Cox proportional
hazard model was used to assess the associations of ALK copy
number alteration and overall survival in both univariate and
multivariate analyses. Kaplan-Meier estimate was used to sum-
marize median overall survival. All the statistical tests were
conducted at the two-sided 0.05 level of significance.
Results
The median OS was 12 months with 45 patients deceased at the
time of analysis, with a median follow-up of 23 months. Table 1
summarizes patient and clinical characteristic for the entire cohort
as well as for patients with more than 4 fold copy number gain in
the FISH analysis.
Recurrent chromosomal gains and losses by aCGH
Analysis by aCGH of the 70 patients included in the study
identified 95 focal and 21 broad (identified as .50% of the
chromosome arm) events. The results of the broad alteration
analysis were largely consistent with the current literature [16–18].
We observed frequent losses of chromosomes 5q (43%), 8p (69%),
9 (p: 48%; q: 41%), 10q (41%), 11p (49%), 17p (51%), and 22q
(40%) and recurrent gains of chromosomes 3q (46%), 5p (48%), 8q
(48%), 19q (34%), and 20 (60%). Three specimens out of 70
harbored minor non-significant alterations (log2 ratio 0–0.8) in
chromosome 2, where ALK gene locus is located. This encouraged
us to conduct a more in-depth search of ALK genomic alterations
and to further characterize the 59ALK deletion seen by FISH in
one patient.
FISH analysis of ALK gene/copy number gains
To further characterize genomic imbalances on chromosome 2,
all samples underwent FISH analysis. One case presented a
deletion of the green signal (59ALK), centromeric to the ALK gene,
and also had gain of the ALK gene fusion signals and 39ALK signal
(Figures 1 and 2). This FISH pattern was interpreted as an ALK
atypical rearrangement as has been described in ALK positive
NSCLC because a single orange (39ALK) signal was seen [19]. In
these cases it is assumed that the deletion is the result of
translocation. Analyses of EML4 as well as other known fusion
partners such as TGF and KIF5 were performed without finding
any translocation of these genes. Even so, it is possible that the
deletion does not cause the ALK translocation and other
molecular techniques need to be applied to further characterize
the FISH findings.
ALK gene copy number gains and amplification were analyzed
in all samples. Two cases presented amplification of ALK. 90% of
samples showed ALK copy number gain due to polysomy of
chromosome 2. All of them had 3 to 6 copies of CEP2 except one
case with high polysomy. Among 70 urothelial tumors, 7 (10%)
demonstrated 2F signals (2 intact ALK loci), 46 (65.7%) had 3–4F
signals present, and 17 (24.3%) had $5F signals (range 5F–11F;
median 6F) in .10% of nuclei (Table 2). The associations of
ALK Alterations in Urothelial Carcinoma
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All patients (N=70) Patients with copy number alteration (N=17)
N % or median (q1, q3) N % or median (q1, q3)
Age 61 63 (54, 68) 15 66 (58, 68)
Sex
Male 52 74% 15 88%
Female 18 16% 2 12%
ECOG PS
02 2 3 1 % 4 2 4 %
1, 2 48 69% 13 76%
Visceral diseases
No 41 59% 7 41%
Yes 29 41% 10 59%
Pathological stage
Stage 0 (Ta) 5 7% 2 12%
Stage I (T1) 5 7% 0 0%
Stage II (T2) 36 51% 8 47%
Stage III (T3, T4) 22 31% 7 41%
Stage IV (L, M) 1 1% 0 0%
Missing 1 1% 0 0%
doi:10.1371/journal.pone.0103325.t001
Figure 1. 1298case –FISH + for ALK variant (green probe missing).
doi:10.1371/journal.pone.0103325.g001
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doi:10.1371/journal.pone.0103325.g002
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OS are summarized in Tables 3 and 4. No significant
association between ALK copy number alteration and clinical
features or overall survival was observed (Figure 3).
Comparison of ALK gene copy number gains to clinical and
pathological features for the 70 patients are summarized in
Table 1. There were no differences between ALK gene copy
number gains and clinical features in all the subgroups (2F, 3–4F
and $5F). OS rates for patients with 2F+324F and .5F were 12
and 16 months respectively. There was no statistically significant
difference between these groups (Figure 3).
ALK protein expression by immunohistochemistry
To further characterize whether ALK protein expression was
affected, immunohistochemistry analysis of all FFPE samples was
performed using the Cell Signaling antibody. Immunohistochem-
istry staining was negative in the tumor with ALK FISH positive
test. Similarly, among tumors with ALK gene copy gain or
amplification, ALK protein expression was not detected. None of
the tumors classified as ALK negative by FISH showed ALK
protein expression by immunohistochemistry.
High-throughput mutational analysis using Oncomap
To have more accurate information on genetic alteration in
these UC samples, mass spectrometry mutation analysis was also
performed for all samples. Ninety-six samples were submitted for
OncoMap: 87/96 (91%) passed all quality control steps. 79% (69/
87) passing samples harbored candidate mutations. In total, 150
candidate mutation calls were made across 47 genes. Overall, 39%
(58/150) of candidate mutations in passing samples were
conservative and 61% (92/150) were aggressive. No mutations
in ALK were found using this platform. ALK P496L candidate
mutation was found in one of the sample but was not confirmed
with HME.
Next-generation sequencing of ALK gene
Since FISH technique gives no information of the specific
sequence and the exact size of the deleted fragment in ALK,
directed analysis of ALK gene was performed by next generation
sequencing (Illumina). Analysis of the region containing P496 only
showed base changes at rates below 1%, reflecting the expected
sequencing error rate. Thus, only the wild-type sequence for the
position P496 was detected and no mutations on ALK were
detected by this technique.
We then extended the search space to the centromere with the
intention to explore potential deletions according to FISH results.
In the new analysis performed on the FISH positive patient, one
read of a pair should match within the ALK locus, 29.37 Mb -
32 Mb, and one read should match at some place towards the
centromere (.10 kb up to position 93.3 Mb). However, at the
coverage level used no deletions could be confirmed with this
approach.
Figure 3. Comparison of OS between $5F patients and 2F+324F.
doi:10.1371/journal.pone.0103325.g003
Table 2. Copy Number Alteration.
N%
2F 71 0
3-4F 46 66
$5F 17 24
doi:10.1371/journal.pone.0103325.t002
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In the present study we interrogate whether the ALK genomic
alterations are of potential clinical relevance in patients with UC.
Our study shows that ALK amplification and copy number gain
but not fusions and translocations occurs in UC but is not
associated with poor outcome in our patients with already bad
prognosis.
ALK gene is located in 2p23 and encodes a transmembrane
tyrosine kinase receptor involved in the development of nervous
system during embryogenesis [20,21]. ALK gene was first shown
to have a role in cancer as part of the fusion gene nucleophosmin
(NPM)-ALK in anaplastic large cell lymphomas(9, 10). Preclinical
studies show that tumors with aberrant activation of ALK tyrosine
kinase are oncogene addicted to ALK intracellular signaling, and
inhibition of the kinase by specific ALK targeting drugs results in
tumor growth arrest and cell death (25).
The best well studied genomic alteration is the translocation
seen in NSCLC patients. The majority of ALK rearrangements
come from an interstitial deletion and inversion in chromosome 2p
resulting in EML4–ALK fusion gene product [22–27].Although
translocation is the most commonly identified mechanism for ALK
activation, amplification and mutation have also been shown to act
as oncogenic events [28–30]. The role of amplification and of copy
number gain, as well as the role of deletion found in tumors like
RMS remains to be determined [27,31–34].
The finding that several tumor types have been identified that
have ALK as an oncogenic driver regardless of their cell of origin
has prompted the creation of the term ‘‘ALKomas’’ implying a
‘‘beyond organ’’ concept classification assuming consequently
responses to ALK inhibitors such as crizotinib [10,35]. Based on
that, exploration of this concept is worthwhile in UC even if the
frequency happens to be low.
In our cohort, aCGH-A found only some minor focal events in
3/70 specimens harboring non-significant alterations in ALK gene
locus region. Since copy number gain has been recently associated
with poor prognosis in several tumors like RMS, RCC and
colorectal cancer (CRC), FISH analysis to assess the impact of
copy number variations of ALK in our cohort was performed. In
our patients, polysomy was frequently found in 90% of the cases
[15,34]. The biological relevance of such finding is uncertain but
could reflect genomic instability. The OS for patients with (2F+32
4F) vs. .5F was found to be 12 and 16 months respectively,
however did not reach statistical significance (Figure 1). Likewise,
there were no differences between ALK gene copy number gains
and clinical features in all the different subgroups (2F, 3–4F and $
5F). A plausible explanation for this lack of a significant difference
between these groups is that it could be related to the natural
history and the aggressive phenotype of our analysis cohort
(metastatic disease requiring chemotherapy) with other genetic
abnormalities beyond ALK gene copy number having a greater
functional role in oncogenesis. Similarly, arm level ALK gene copy
number gain as observed in this analysis may be unrelated to the
driver oncogenic events.
Generally, patients with ALK copy gain have not shown to have
detectable ALK protein expression as assessed by IHC except for a
recent publication by van Gaal and colleagues [27,29,34,36]. In
our series, no patient with gene copy gain or amplification tested
positive by IHC. This is similar to that observed in CRC where
increased ALK gene copy number did not translate to increased
ALK protein expression [37]. However, this is not the case for
patients being categorized as FISH positive, where this positivity
strongly correlates with IHC. Of note, in lung cancer, a positive
ALK FISH test and ALK IHC have been proposed as screening
tools to detect ALK alterations being considered sufficiently
sensitive to indicate treatment with crizotinib [37]. Moreover, in
NSCLC, abnormal FISH signal patterns have varied from a single
split signal to more complex signal patterns, such as deletions of
the green 59 end of the ALK probe, gain of the split or 59ALK
signal or both. These variant ALK FISH signals usually, but not
always, represent an ALK translocation and therefore the finding
of a loss of the 59ALK signal has been considered to be a
presumptive evidence of an ALK gene rearrangement [37].
In our series, the patient with a FISH positive result had a
variant signal pattern that did not correlate with ALK protein
expression as assessed by IHC. The case was interpreted as having
a deletion in the ALK region due to loss of the green 59 end of the
ALK signal, after excluding the possibility it could be related to
alternative translocation partners [Kinesin family 5B (KIF5B) and
TRK-fused gene (TFG)]. In our patient we did not test for the
rearrangement of other fusion partners to ALK such as C2orf44,
KIF5B, NPM1, VCL, TFG, RET, ROS, and VCL [38–43]. These
genes have all been shown to be partners of ALK in lung cancer
[44].
Finally, ALK Mutations have been described in 10.4% of
neuroblastoma samples but not in other pediatric tumors like
RMS, Ewing sarcoma, or DSRCT and only occasionally in other
solid tumors like CRC [45,46]. In lung cancers, ALK mutations
appear to develop during clinical treatment with crizotinib and
their generation probably renders EML4-ALK resistant not only
to crizotinib but also to other ALK inhibitors [47]. In our series, no
ALK P496L mutation was observed. In our study the limitations of
the platform used limits our conclusions of the mutation analysis.
The absence or very low percentage of activating mutation of ALK
described in the majority of adult solid tumors tested support our
analysis that these alterations are not relevant events in UC.
Table 3. Association of ALK copy number alteration with ECOG PS and visceral disease.
ALK .4 copies P-value
No Yes
ECOG PS 0.55
01 8 4
1, 2 35 13
Visceral disease 0.16
No 34 7
Yes 19 10
doi:10.1371/journal.pone.0103325.t003
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confirmed with the sequencing approach used. Discordantly,
mapping read pairs suggesting deletions resolved into correctly
mapping read pairs that were in agreement with the insert size of
the library when a single mismatch between read and reference
genome was tolerated. Thus, these pairs do not support deletions
at the ALK locus. The average read coverage across the ALK
region was 56and if only a small proportion of cells contained a
deletion, we would not have been able to detect it. Because we
suspect the deletion was close to the centromere, we might have
missed it and might not have been able to confirm it by next
generation sequencing.
To summarize, the increasing evidence that ALK alterations are
seen in tumors from different origins highlights the concept of
stratifying tumors according to oncogenic genotypes as opposed to
tissue type when considering treatment strategies. The finding of
the absence of ALK rearrangement together with no activating
mutation in ALK suggests that these alterations might not be
pathogenic events in UC. The utility of testing ALK inhibitors in
UC is not supported by this data, although in the absence of
effective alternative agents testing ALK inhibitors may still be
warranted.
In conclusion, ALK genomic alterations are rare and probably
without prognostic implications in UC. The potential for testing
ALK inhibitors in patients with deletions and copy number
changes UC merits further investigation in a larger expanded
cohort of UCs, but might be restricted to the infrequent finding of
a FISH positive patient.
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